Physician
Valley Regional Hospital INC.
Valley Regional Hospital INC. was paid $9.99M by Medicaid between Jan 2018 and Nov 2024, across 136 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoVALLEY REGIONAL HOSPITAL INC.
CLAREMONT, NH 03743
CLAREMONT, NH 03743
33aNPI1306933619assigned 10/06/2006
33bProvider typeSurgery Physician
28Total paid$9.99M
24GClaims217,872
24DCodes billed136
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Surgery Physician providers in New Hampshire
Rank by total paid#1 of 8
Median peer was paid$395.14
This provider vs. median25,285×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,533 | $1.46M | |
| 2019 | 44,970 | $1.78M | |
| 2020 | 38,440 | $1.72M | |
| 2021 | 40,737 | $2.14M | |
| 2022 | 32,921 | $1.85M | |
| 2023 | 11,461 | $605K | |
| 2024incomplete | 6,810 | $420K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 15,181 | 11,829 | $2.72M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 1,218 | 924 | $1.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 8,007 | 4,855 | $1000K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 5,390 | 2,676 | $807K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 1,833 | 1,260 | $468K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 4.1% | 5,643 | 1,485 | $409K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.6% | 5,520 | 4,594 | $260K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 5,023 | 1,369 | $218K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 5,841 | 3,643 | $216K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 3,001 | 2,075 | $177K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,696 | 1,600 | $176K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.7% | 2,028 | 1,672 | $174K |
124 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 2,380 | $158K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 194 | $145K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 3,281 | $143K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 2,247 | $131K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 2,979 | $128K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.2% | 12,534 | $121K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 2,996 | $109K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 1,830 | $105K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 102 | $89K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 254 | $82K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 8,162 | $71K |
| 80053 | Comprehensive metabolic panel | <1% | 12,051 | $66K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,488 | $63K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,910 | $56K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,555 | $48K |
| 73630 | <1% | 571 | $45K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,079 | $34K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 447 | $33K |
| 73130 | <1% | 308 | $32K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,245 | $31K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,169 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 161 | $31K |
| 73610 | <1% | 307 | $29K | |
| 96376 | <1% | 637 | $26K | |
| 97162 | <1% | 317 | $24K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,598 | $23K |
| 80061 | Lipid panel | <1% | 1,973 | $20K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,295 | $19K |
| 84484 | <1% | 5,348 | $19K | |
| 73562 | <1% | 194 | $18K | |
| 73110 | <1% | 178 | $18K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 311 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,153 | $16K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,043 | $15K |
| 80306 | <1% | 2,006 | $15K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 618 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 602 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 537 | $11K |
| 87070 | <1% | 1,844 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,462 | $10K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 552 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 328 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,488 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,997 | $8K |
| 83690 | <1% | 2,234 | $8K | |
| 73030 | <1% | 105 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 566 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 141 | $7K |
| 87077 | <1% | 1,405 | $6K | |
| 84703 | <1% | 1,218 | $6K | |
| 97161 | <1% | 63 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,012 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 146 | $6K |
| 81001 | <1% | 3,744 | $5K | |
| 87040 | <1% | 1,448 | $5K | |
| 81025 | <1% | 1,254 | $5K | |
| 71250 | <1% | 14 | $5K | |
| 87186 | <1% | 1,087 | $5K | |
| 83880 | <1% | 460 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,556 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 177 | $4K |
| 83735 | <1% | 1,645 | $4K | |
| 83605 | <1% | 998 | $3K | |
| 82077 | <1% | 326 | $3K | |
| 85379 | <1% | 559 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 63 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,925 | $3K |
| 80143 | <1% | 292 | $3K | |
| 94375 | <1% | 30 | $3K | |
| 80179 | <1% | 266 | $3K | |
| 87807 | <1% | 258 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,811 | $3K |
| 84439 | <1% | 356 | $2K | |
| 74018 | <1% | 22 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 295 | $2K |
| 81003 | <1% | 2,198 | $2K | |
| 80076 | <1% | 338 | $2K | |
| 90715 | <1% | 58 | $2K | |
| 85610 | <1% | 917 | $2K | |
| 82607 | <1% | 194 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 322 | $2K |
| 72100 | <1% | 13 | $1K | |
| 86140 | <1% | 397 | $1K | |
| 76376 | <1% | 19 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 166 | $1K |
| 87147 | <1% | 212 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 69 | $1K |
| 81002 | <1% | 668 | $1K | |
| 96367 | <1% | 17 | $981.47 | |
| 86803 | <1% | 89 | $968.17 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 34 | $952.03 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 106 | $872.42 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 488 | $845.49 |
| 99442 | <1% | 47 | $844.15 | |
| 36416 | <1% | 459 | $813.37 | |
| 85027 | <1% | 199 | $636.48 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 105 | $541.15 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 24 | $535.51 |
| 81015 | <1% | 373 | $467.00 | |
| 80050 | General health panel | <1% | 54 | $391.37 |
| 82803 | <1% | 35 | $357.75 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 27 | $347.97 |
| 82728 | <1% | 34 | $301.93 | |
| 83655 | <1% | 29 | $297.08 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12 | $296.16 |
| G0008 | Administration of influenza virus vaccine | <1% | 260 | $264.99 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 117 | $248.81 |
| 90686 | <1% | 203 | $223.92 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 52 | $219.02 |
| 82248 | <1% | 44 | $184.83 | |
| 85652 | <1% | 94 | $169.87 | |
| 83550 | <1% | 38 | $144.31 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 70 | $138.06 |
| 83540 | <1% | 38 | $107.01 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 64 | $83.89 |
| 90653 | <1% | 44 | $78.93 | |
| 87205 | <1% | 28 | $72.86 | |
| 82150 | <1% | 16 | $60.93 | |
| 85730 | <1% | 20 | $46.89 | |
| 87210 | <1% | 14 | $37.28 | |
| 85014 | <1% | 14 | $25.96 | |
| 85018 | <1% | 14 | $25.96 | |
| 90662 | <1% | 17 | $17.60 | |
| A9270 | Non-covered item or service | 0% | 434 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOSTER, MATTHEW (CEO)
| Provider | Location | Paid |
|---|---|---|
| Valley Regional Hospital, INC. | Claremont, NH | $875K |
| Valley Regional Hospital, INC | Claremont, NH | $782K |
| Valley Regional Hospital ,INC. | Claremont, NH | $600K |
| Valley Regional Hospital, INC. | Claremont, NH | $183K |
| Valley Regional Hospital, INC. | Claremont, NH | $21K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.